DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Eli Lilly - 5 Novo - 4 Lilly - 2 Mounjaro - 2 Cigna - 1 Geoff Meacham - 1 Meacham - 1 Yuri Khodjamirian - 1
Top related locs:
U.S Germany Europe United States Oslo Norway mull Tema
Top related orgs:
Novo Nordisk - 5 drugmakers Novo Nordisk - 3 CNBC - 1 Bank of America - 1 Centers for Disease Control - 1 Zealand Pharma - 1 Viking Therapeutics - 1 Zealand - 1

Search resuls for: "drugmakers Novo Nordisk"


6 mentions found


☆ Cigna will cap how much insurance can spend on weight loss drugs as it tries to expand coverage
  + stars: | 2024-03-07 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +2 min
Cigna on Thursday said it will limit how much health plans and employers spend on weight loss drugs each year in a bid to expand insurance coverage for those highly popular treatments. The effort by insurance giant Cigna could make weight loss treatments more accessible. They deferred CNBC to Cigna for details on the insurance spending cap. Those medicines treat weight loss and diabetes by mimicking one or more hormones produced in the gut to suppress appetite and regulate blood sugar. Cigna said providing "financial predictability" through a cost cap will allow health plans and employers to better plan to manage GLP-1 spending.
Persons: Cigna, Eli Lilly Organizations: CNBC, drugmakers Novo Nordisk, Novo Nordisk Locations: Oslo, Norway, mull
☆ Viking stock doubled Tuesday. Here's where the next moves in the obesity space could come from
  + stars: | 2024-02-27 | by ( Christina Cheddar Berk | In | ) www.cnbc.com   time to read: +8 min
VKTX YTD mountain Viking shares year to date Then, Viking shares more than doubled in trading on Tuesday, putting the stock on pace to report a more than 300% year-to-date gain, after the company said its GLP-1/GIP receptor agonist VK2735 hit all its primary goals in a phase 2 clinical trial. The Tema Cardiovascular and Metabolic ETF (HRTS) , which is up 12% year to date, owns Novo, Lilly and Viking. Still early days Some analysts and investors admit it is still very early days for obesity treatment and many questions remain to be answered. "We continue to expect above consensus growth in the space, as we are bullish on adoption from payers and broader obesity uptake," Meacham wrote. For obesity only, Lilly has already gained a 38% share, despite only being in the market for 13 weeks, he said.
Persons: Eli Lilly, Geoff Meacham, Meacham, Lilly, Yuri Khodjamirian, Khodjamirian, Jeff Jonas, Becton Dickinson, Novo, BofA's Meacham, What's, Tema's, it's, Gabelli's Jonas, he's, William Blair, Andy Hsieh, Hsieh Organizations: Novo Nordisk, Bank of America, Centers for Disease Control, Zealand Pharma, Viking Therapeutics, Zealand, Food and Drug Administration, Novo, Metabolic, Therapeutics, Pharmaceuticals, Rock, AstraZeneca, Roche, Gabelli Funds, FDA, Viking, Merck, Pfizer Locations: U.S, Tema, Novo Nordisk's, GLP, Lilly
☆ Missed the Novo and Lilly rally? These 4 under-the-radar anti-obesity drug stocks could soar, Berenberg says – giving one 44% upside
  + stars: | 2024-01-22 | by ( Ganesh Rao | ) www.cnbc.com   time to read: +2 min
The anti-obesity drug market is expected to remain in focus this year after a bumper 2023 for weight loss drugmakers Novo Nordisk and Eli Lilly , according to Berenberg. GLP-1 drugs encourage the production of hormones that cause weight loss through reduced appetite. Nevertheless, Berenberg's analysts believe the bigger, underappreciated, near-term opportunity lies with companies preparing to launch generic versions of the first-generation GLP-1 drugs. Under-the-radar picks Sartorius and SKAN Group, Berenberg's "under-the-radar" pick, are also expected to benefit from manufacturing generic GLP-1 drugs. The investment bank sees Sartorius benefiting from the growing commercialization of GLP-1 drugs and forecasts shares to rise by 27% over the next 12 months.
Persons: Eli Lilly, Novo, Sandoz, Berenberg Organizations: Novo Nordisk, —, Nordisk, Novo Nordisk's Victoza, SKAN Locations: Germany, Europe, Sandoz, United States
☆ Novo Nordish and Eli Lilly cash in on blockbuster weight-loss drugs
  + stars: | 2023-11-02 | by ( Manav Tanneeru | Samantha Delouya | ) edition.cnn.com   time to read: +2 min
New York CNN —As prescriptions for weight-loss and diabetes drugs skyrocket, so too has revenue for drugmakers Novo Nordisk and Eli Lilly. On Thursday, Novo Nordisk, the Denmark-based company behind Ozempic and Wegovy, reported a 29% increase in sales to $8.4 billion for the third quarter. The pharmaceutical companies are two of the biggest beneficiaries of the recent weight-loss drug frenzy, with Novo Nordisk catapulting to Europe’s most valuable company in September. Novo Nordisk reported that its obesity care sales grew 174% in the first nine months of 2023, mainly driven by US demand. The success of Novo Nordisk and Eli Lilly’s drugs has inspired other companies to dive into the prescription weight-loss business, including WeightWatchers, now known as WW International.
Persons: Eli Lilly, Mounjaro, Wegovy, Novo, –, Eli Lilly’s Organizations: New, New York CNN, drugmakers Novo Nordisk, Novo Nordisk, Novo Nordisk catapulting, International Locations: New York, Denmark, United States, Novo
☆ Demand for weight-loss drugs fuels global rise in counterfeits
  + stars: | 2023-10-20 | by ( Patrick Wingrove Maggie Fick | Patrick Wingrove | Maggie Fick | ) www.reuters.com   time to read: +5 min
Homeland Security, as well as companies that help identify counterfeit products such as Israel’s BrandShield. Fake weight-loss drugs will be a key focus in the agency’s annual counterfeit medicines report, due next year, the official said. “We have counterfeit products and stolen products,” the official said. "We will look online and if we find something that infringes (obesity drug trademarks) we'll get it taken down,” said Yoav Keren, BrandShield CEO. When a consumer buys those fakes, “what you get are expired drugs, counterfeit drugs, or nothing,” he added.
Persons: George Frey, Eli Lilly, BrandShield, Novo’s Ozempic, ”, Jim Mancuso, Mancuso, Europol, Novo, Lilly, “, Ozempic, Yoav Keren, MHRA, Eli, Mounjaro, Patrick Wingrove, Aurora Ellis Organizations: Novo Nordisk, Pharmacy, REUTERS, Novo Nordisk’s, Pharmaceutical Security Institute, drugmakers Novo Nordisk, Europol, Interpol, U.S . Homeland Security, U.S . Food, Drug Administration, U.S . Department of Homeland, Coordination Center, PSI, Medicines, Healthcare, Agency, Health Organization, Ireland’s, Products Regulatory Authority, Reuters, Thomson Locations: Provo , Utah, U.S, America, Europe, Germany, Egypt, Russia, North America
☆ Pharma’s obesity gold rush will have limits: podcast
  + stars: | 2023-05-11 | by ( Aimee Donnellan | ) www.reuters.com   time to read: 1 min
LONDON, May 11 (Reuters Breakingviews) - Drugmakers Novo Nordisk and Eli Lilly are vying for a large slab of the weight loss medications market, which analysts reckon could be worth $100 bln by 2031. In this Viewsroom podcast, Breakingviews columnists discuss how investor optimism in a booming market is unwarranted. Listen to the podcastFollow @aimeedonnellan on Twitter(The author is a Reuters Breakingviews columnist. Subscribe to Breakingviews’ podcasts, Viewsroom and The Exchange. They do not reflect the views of Reuters News, which, under the Trust Principles, is committed to integrity, independence, and freedom from bias.
0 next >>
Total: 6